Abstracts tagged "Physical function and psoriatic arthritis"

Abstract Number: 633 • 2018 ACR/ARHP Annual Meeting
The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
Dafna D Gladman¹, Wolf-Henning Boehncke², Alice B Gottlieb³, Philip Helliwell⁴, Peter Nash⁵, Xie L. Xu⁶, Stephen Xu⁶, Yuhua Wang⁶, Elizabeth C Hsia^6,7, Chetan S Karyekar⁶ and Atul A. Deodhar⁸, ¹Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ²U of Geneva, Geneva, Switzerland, ³NY Medical College, Metropolitan Hospital, NY, NY, ⁴U of Leeds, Leeds, United Kingdom, ⁵U of Queensland, Brisbane, Australia, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷U Penn School of Medicine, Phila, PA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: In a Ph2 study, GUS was shown to be safe&effective in pts w/active PsA. We evaluated effect of GUS on dactylitis in subset of…
Abstract Number: 686 • 2018 ACR/ARHP Annual Meeting
Five-Year Efficacy and Safety of Apremilast Treatment in Subjects with Psa: A Pooled Analysis of the 3 Phase III Studies
Arthur Kavanaugh¹, Dafna D Gladman², Christopher J. Edwards³, Georg Schett⁴, Benoit Guerette⁵, Nikolay Delev⁵, Lichen Teng⁵, Maria Paris⁵ and Philip J. Mease⁶, ¹University of California, San Diego, School of Medicine, La Jolla, CA, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Southampton, Southampton, United Kingdom, ⁴Friedrich-Alexander-Universität Erlangen, Nürnberg und Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Celgene Corporation, Summit, NJ, ⁶Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Long-term apremilast (APR) efficacy and safety were evaluated for up to 5 yrs in adults with active PsA in the phase III PALACE 1-3…
Abstract Number: 1617 • 2018 ACR/ARHP Annual Meeting
Influence of Disease Activity in the Physical Activity of Psoriatic Arthritis Patients
M. Vanesa Hernandez-Hernandez¹, Hiurma Sanchez-Perez², Esmeralda Delgado-Frías¹, Iván Ferraz-Amaro³ and Federico Díaz-González⁴, ¹Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, ²Rheumatology, Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, ³Rheumatology Division, Hospital Insular de Gran Canaria, La Laguna, Spain, ⁴University of La Laguna, Hospital Universitario de Canarias, La Laguna, Spain
Background/Purpose: It is generally assumed that patients with chronic arthritis conditions tend to exercise less than what is currently recommended. Although several evidences support this…
Abstract Number: 1634 • 2018 ACR/ARHP Annual Meeting
The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study
Cristina Fernández-Carballido¹, Maria Auxiliadora Martin², María Carmen García-Gómez³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, Rosario García-Vicuña⁷, Celia Erausquin⁸, Francisco J Lopez-Longo⁹, María D Sanchez-Gonzalez¹⁰, Alfonso Corrales¹¹, Estefania Quesda-Masachs¹², Eugenio Chamizo Carmona¹³, Carmen Barbadillo¹⁴, Javier Bachiller¹⁵, Tatiana Cobo-Ibáñez¹⁶, Ana Turrión Nieves¹⁷, Emilio Giner Serret¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay¹¹, ¹Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁴Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ⁸Rheumatology, Hospital de Gran Canaria Dr Negrin, Las Palmas GC, Spain, ⁹Rheumatology Department, Hospital Gregorio Marañón, Madrid, Spain, ¹⁰Rheumatology, Hospital Clínico, Salamanca, Spain, ¹¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ¹²Rheumatology Division, Hospital Vall Hebrón, Barcelona, Spain, ¹³Rheumatology, Hospital de Mérida, Merida, Spain, ¹⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁵Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ¹⁶Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ¹⁷Rheumatology, Hospital Universitario de Salamanca. Spain, Salamanca, Spain, ¹⁸Rheumatology, H Obispo Polanco, Teruel, Spain, ¹⁹Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain
Background/Purpose: Functional status gets worse with comorbidities regardless of disease activity in patients with rheumatoid arthritis (RA). However, the impact of comorbidities on physical function…
Abstract Number: 1644 • 2018 ACR/ARHP Annual Meeting
Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Ana-Maria Orbai¹, Jessica Walsh², Peter Nash³, Lichen Teng⁴, Benoit Guerette⁴ and Rieke Alten⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Utah School of Medicine, Salt Lake City, UT, USA, Salt Lake City, UT, ³University of Queensland, Brisbane, Australia, ⁴Celgene Corporation, Summit, NJ, ⁵Schlosspark-Klinik University Medicine, Berlin, Germany
Background/Purpose: Stiffness is an important component of inflammatory arthritis and plays a role in PsA flare. Patients with inflammatory arthritis report difficulty with activities, “slowing…
Abstract Number: 1588 • 2014 ACR/ARHP Annual Meeting
Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life
Diego Roger Silva¹, Fabio Jennings¹, Emilia Moreira¹ and Jamil Natour², ¹Rheumatology Division, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, ²Internal Medicine, Escola Paulista de Medicina/ Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose Psoriatic arthritis (PSA) is a chronic inflammatory arthritis, defined as the association of inflammatory arthropathy and skin psoriasis. The literature is still very scarce…
Abstract Number: 1559 • 2014 ACR/ARHP Annual Meeting
Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients
Arthur Kavanaugh¹, Lluís Puig Sanz², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Shu Li⁵, Yin You⁵, Alan M. Mendelsohn⁶, Michael Song⁵, Proton Rahman⁷ and Iain B. McInnes⁸, ¹University of California San Diego, La Jolla, CA, ²Dermatology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC., Spring House, PA, ⁶Immunology, Janssen Research & Development, LLC., Spring House, PA, ⁷Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁸Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate the association of improvements in tender and swollen joint counts (TJC, SJC), psoriasis skin involvement, and dactylitis/enthesitis (in patients affected at baseline)…
Abstract Number: 331 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvement In Physical Function In Patients With Psoriatic Arthritis: Results From Three Phase 3, Randomized, Controlled Trials
Georg Schett¹, Philip J. Mease², Dafna D. Gladman³, Arthur Kavanaugh⁴, Adewale O. Adebajo⁵, Juan J. Gomez-Reino⁶, Jürgen Wollenhaupt⁷, Maurizio Cutolo⁸, Eric Lespessailles⁹, Kamal Shah¹⁰, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California San Diego, San Diego, CA, ⁵Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom, ⁶Hospital Clinico Universitario, Santiago, Spain, ⁷Schön Klinik Hamburg Eilbek, Hamburg, Germany, ⁸University of Genova, Genova, Italy, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University of Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].